These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20947480)

  • 41. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?
    Besson A; Assoian RK; Roberts JM
    Nat Rev Cancer; 2004 Dec; 4(12):948-55. PubMed ID: 15573116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New microtubule-inhibiting anticancer agents.
    Chen SM; Meng LH; Ding J
    Expert Opin Investig Drugs; 2010 Mar; 19(3):329-43. PubMed ID: 20141350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multifaceted ability of naturally occurring polyphenols against metastatic cancer.
    Zhou Q; Bennett LL; Zhou S
    Clin Exp Pharmacol Physiol; 2016 Apr; 43(4):394-409. PubMed ID: 26773801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer.
    Donald CD; Cooper CR; Harris-Hooker S; Emmett N; Scanlon M; Cooke DB
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1033-8. PubMed ID: 11785653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
    Pàez-Ribes M; Allen E; Hudock J; Takeda T; Okuyama H; Viñals F; Inoue M; Bergers G; Hanahan D; Casanovas O
    Cancer Cell; 2009 Mar; 15(3):220-31. PubMed ID: 19249680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multimodal Nanomedicine Strategies for Targeting Cancer Cells as well as Cancer Stem Cell Signalling Mechanisms.
    Kanwar JR; Samarasinghe RM; Kamalapuram SK; Kanwar RK
    Mini Rev Med Chem; 2017; 17(18):1688-1695. PubMed ID: 26891936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell motility and cytoskeletal regulation in invasion and metastasis.
    Kedrin D; van Rheenen J; Hernandez L; Condeelis J; Segall JE
    J Mammary Gland Biol Neoplasia; 2007 Sep; 12(2-3):143-52. PubMed ID: 17557195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting TGFbeta-mediated processes in cancer.
    Romano MF
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):253-63. PubMed ID: 19333871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Actin regulators in cancer progression and metastases: From structure and function to cytoskeletal dynamics.
    Biber G; Ben-Shmuel A; Sabag B; Barda-Saad M
    Int Rev Cell Mol Biol; 2020; 356():131-196. PubMed ID: 33066873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are We Ready for Migrastatics?
    Solomon J; Raškova M; Rösel D; Brábek J; Gil-Henn H
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological strategies and micrometastasis: what is known? What must be done?
    Perret GY
    Minerva Med; 2010 Jun; 101(3):163-78. PubMed ID: 20562804
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth.
    Chakrabarti KR; Hessler L; Bhandary L; Martin SS
    Clin Cancer Res; 2015 Dec; 21(23):5209-5214. PubMed ID: 26463706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer therapy: an evolved approach.
    Willyard C
    Nature; 2016 Apr; 532(7598):166-8. PubMed ID: 27075079
    [No Abstract]   [Full Text] [Related]  

  • 55. Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment.
    Riggi N; Aguet M; Stamenkovic I
    Annu Rev Pathol; 2018 Jan; 13():117-140. PubMed ID: 29068753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.
    Mrozik KM; Blaschuk OW; Cheong CM; Zannettino ACW; Vandyke K
    BMC Cancer; 2018 Oct; 18(1):939. PubMed ID: 30285678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer?
    Pervaiz S
    Curr Pharm Des; 2002; 8(19):1723-34. PubMed ID: 12171544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
    Hua H; Kong Q; Yin J; Zhang J; Jiang Y
    J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of β-glucans on cancer metastasis.
    Yoon TJ; Koppula S; Lee KH
    Anticancer Agents Med Chem; 2013 Jun; 13(5):699-708. PubMed ID: 23140352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitors for metastasis development.
    Lang K; Drell TL; Zaenker KS; Entschladen F
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):69-80. PubMed ID: 18221027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.